$45.58
Revenue is up for the last 2 quarters, 290.62M → 298.97M (in $), with an average increase of 2.8% per quarter
Netprofit is up for the last 3 quarters, -28.40M → 3.45M (in $), with an average increase of 312.0% per quarter
In the last 1 year, 10x Genomics Inc has given 39.4% return, outperforming this stock by 85.3%
0.57%
Downside
Day's Volatility :4.09%
Upside
3.54%
0.57%
Downside
52 Weeks Volatility :50.73%
Upside
50.45%
Period | Omnicell Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -34.08% | -0.9% | 0.0% |
6 Months | -18.95% | 1.5% | 1.0% |
1 Year | -45.89% | 7.1% | 6.4% |
3 Years | -36.39% | 25.9% | 19.9% |
Market Capitalization | 2.1B |
Book Value | $25.74 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -0.51 |
PEG Ratio | 2.28 |
Wall Street Target Price | 73.43 |
Profit Margin | -1.88% |
Operating Margin TTM | -1.79% |
Return On Assets TTM | -0.64% |
Return On Equity TTM | -2.06% |
Revenue TTM | 1.2B |
Revenue Per Share TTM | 27.58 |
Quarterly Revenue Growth YOY | -9.8% |
Gross Profit TTM | 596.7M |
EBITDA | 36.3M |
Diluted Eps TTM | -0.51 |
Quarterly Earnings Growth YOY | -0.62 |
EPS Estimate Current Year | 1.8 |
EPS Estimate Next Year | 2.34 |
EPS Estimate Current Quarter | 0.28 |
EPS Estimate Next Quarter | 0.45 |
What analysts predicted
Upside of 61.1%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 716.2M | ↑ 3.4% |
Net Income | 20.6M | ↑ 3317.08% |
Net Profit Margin | 2.88% | ↑ 2.79% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 787.3M | ↑ 9.93% |
Net Income | 37.7M | ↑ 83.11% |
Net Profit Margin | 4.79% | ↑ 1.91% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 897.0M | ↑ 13.94% |
Net Income | 61.3M | ↑ 62.58% |
Net Profit Margin | 6.84% | ↑ 2.05% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 892.2M | ↓ 0.54% |
Net Income | 32.2M | ↓ 47.51% |
Net Profit Margin | 3.61% | ↓ 3.23% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 1.1B | ↑ 26.88% |
Net Income | 77.8M | ↑ 141.81% |
Net Profit Margin | 6.88% | ↑ 3.27% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.3B | ↑ 14.48% |
Net Income | 5.6M | ↓ 92.74% |
Net Profit Margin | 0.44% | ↓ 6.44% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 318.8M | ↑ 2.51% |
Net Income | 8.2M | ↓ 41.26% |
Net Profit Margin | 2.58% | ↓ 1.92% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 331.4M | ↑ 3.94% |
Net Income | 9.1M | ↑ 10.42% |
Net Profit Margin | 2.74% | ↑ 0.16% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 348.1M | ↑ 5.03% |
Net Income | 16.8M | ↑ 84.96% |
Net Profit Margin | 4.82% | ↑ 2.08% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 297.7M | ↓ 14.48% |
Net Income | -28.4M | ↓ 269.36% |
Net Profit Margin | -9.54% | ↓ 14.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 290.6M | ↓ 2.37% |
Net Income | -15.0M | ↓ 47.2% |
Net Profit Margin | -5.16% | ↑ 4.38% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 299.0M | ↑ 2.87% |
Net Income | 3.5M | ↓ 123.01% |
Net Profit Margin | 1.15% | ↑ 6.31% |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 980.3M | ↑ 4.83% |
Total Liabilities | 463.1M | ↓ 8.02% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.1B | ↑ 10.3% |
Total Liabilities | 401.6M | ↓ 13.28% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.2B | ↑ 14.76% |
Total Liabilities | 395.6M | ↓ 1.51% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 47.04% |
Total Liabilities | 857.0M | ↑ 116.66% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 2.1B | ↑ 17.43% |
Total Liabilities | 995.8M | ↑ 16.2% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 2.2B | ↑ 1.74% |
Total Liabilities | 1.0B | ↑ 4.87% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↓ 0.93% |
Total Liabilities | 1.0B | ↑ 5.23% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.1B | ↑ 0.42% |
Total Liabilities | 1.0B | ↓ 0.86% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 2.26% |
Total Liabilities | 1.0B | ↑ 0.53% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↑ 1.43% |
Total Liabilities | 1.1B | ↑ 3.48% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.3B | ↑ 1.81% |
Total Liabilities | 1.1B | ↑ 2.56% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.2B | ↓ 2.53% |
Total Liabilities | 1.0B | ↓ 7.04% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 24.8M | ↓ 48.19% |
Investing Cash Flow | -35.0M | ↓ 89.75% |
Financing Cash Flow | -9.9M | ↓ 103.72% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 104.0M | ↑ 318.64% |
Investing Cash Flow | -54.4M | ↑ 55.41% |
Financing Cash Flow | -13.6M | ↑ 37.66% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 145.0M | ↑ 39.48% |
Investing Cash Flow | -61.7M | ↑ 13.41% |
Financing Cash Flow | -23.5M | ↑ 72.68% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 185.9M | ↑ 28.18% |
Investing Cash Flow | -279.9M | ↑ 353.86% |
Financing Cash Flow | 456.3M | ↓ 2043.31% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 231.8M | ↑ 24.72% |
Investing Cash Flow | -412.5M | ↑ 47.39% |
Financing Cash Flow | 47.4M | ↓ 89.62% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 77.8M | ↓ 66.45% |
Investing Cash Flow | -58.7M | ↓ 85.78% |
Financing Cash Flow | -21.0M | ↓ 144.24% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -16.0M | ↓ 126.82% |
Investing Cash Flow | -18.7M | ↓ 90.26% |
Financing Cash Flow | -32.1M | ↓ 581.83% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -9.6M | ↓ 40.29% |
Investing Cash Flow | -6.8M | ↓ 63.61% |
Financing Cash Flow | -1.5M | ↓ 95.48% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 21.2M | ↓ 321.7% |
Investing Cash Flow | -15.9M | ↑ 132.76% |
Financing Cash Flow | 9.1M | ↓ 723.69% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 82.2M | ↑ 287.97% |
Investing Cash Flow | -17.3M | ↑ 8.73% |
Financing Cash Flow | 3.6M | ↓ 60.67% |
Sell
Neutral
Buy
Omnicell Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Omnicell Inc | -19.8% | -18.95% | -45.89% | -36.39% | -36.61% |
![]() R1 Rcm Inc | -10.03% | 3.5% | -17.83% | -10.3% | 55.68% |
![]() 10x Genomics Inc | -13.51% | -17.89% | 39.41% | -67.26% | -22.54% |
![]() Veeva Systems Inc. | 4.73% | 12.31% | 23.67% | -29.27% | 86.9% |
![]() Ge Healthcare Technologies Inc. | -4.47% | -13.32% | 9.46% | 9.46% | 9.46% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Omnicell Inc | 470.14 | NA | 2.28 | 1.8 | -0.02 | -0.01 | 0.0 | 25.74 |
![]() R1 Rcm Inc | 128.18 | NA | 0.77 | 0.06 | -0.02 | 0.02 | 0.0 | 6.55 |
![]() 10x Genomics Inc | NA | NA | NA | -1.69 | -0.22 | -0.11 | 0.0 | 6.76 |
![]() Veeva Systems Inc. | 60.98 | 60.98 | 1.27 | 4.18 | 0.15 | 0.05 | 0.0 | 25.85 |
![]() Ge Healthcare Technologies Inc. | 19.51 | 19.51 | NA | 3.8 | 0.15 | 0.06 | 0.0 | 15.62 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Omnicell Inc | Buy | $2.1B | -36.61% | 470.14 | -1.88% |
![]() R1 Rcm Inc | Buy | $6.6B | 55.68% | 128.18 | -3.09% |
![]() 10x Genomics Inc | Buy | $6.3B | -22.54% | NA | -30.31% |
![]() Veeva Systems Inc. | Buy | $32.5B | 86.9% | 60.98 | 24.2% |
![]() Ge Healthcare Technologies Inc. | Buy | $31.5B | 9.46% | 19.51 | 9.62% |
BlackRock Inc
Vanguard Group Inc
Wellington Management Company LLP
State Street Corporation
ClearBridge Advisors, LLC
Bank of New York Mellon Corp
since 1992, omnicell has been creating new efficiencies to improve patient care, anywhere it is delivered. omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. omnicell’s automated hardware/software systems for medication dispensing include solutions from the point of entry into the hospital through the central pharmacy, nursing unit, operating room, and patient bedside. our supply management systems promote greater cost control and charge capture for payer reimbursement, and improve management and reordering of inventory. omnicell® products range from high-security, closed-cabinet systems and software to open-shelf and combination systems in the nursing unit, cath lab, and operating room. more than 3,200 customers worldwide have utilized omnice
Organization | Omnicell Inc |
Employees | 3780 |
CEO | Mr. Randall A. Lipps |
Industry | Technology Services |
Caci International Inc
$45.58
-6.02%
Blackrock Short Maturity Bond Etf
$45.58
-6.02%
Central Garden & Pet Co
$45.58
-6.02%
Qifu Technology Inc
$45.58
-6.02%
Cubesmart
$45.58
-6.02%
Dlocal Limited
$45.58
-6.02%
Axa Equitable Holdings, Inc.
$45.58
-6.02%
Consol Energy Inc.
$45.58
-6.02%
Shoals Technologies Group, Inc.
$45.58
-6.02%